ChAd63 MSP1 + ChAd63 ME-TRAP + MVA MSP1 + MVA ME-TRAP

This represents a heterologous prime-boost malaria vaccine regimen developed by the University of Oxford, evaluated in Phase I/IIa clinical trials (e.g., NCT01142765). The regimen utilizes two distinct viral vector platforms: replication-deficient chimpanzee adenovirus 63 (ChAd63, also known as AdCh63) and Modified Vaccinia Ankara (MVA). These vectors are engineered to express two key antigens from the *Plasmodium falciparum* parasite: Merozoite Surface Protein 1 (MSP1), which targets the blood stage of infection, and Multiple-Epitope Thrombospondin-Related Adhesion Protein (ME-TRAP), which targets the liver stage. The immunization strategy typically involves a prime with the ChAd63-vectored vaccines followed by a boost with the MVA-vectored vaccines to stimulate both potent T-cell and antibody-mediated immune responses. Efficacy is often assessed using Controlled Human Malaria Infection (CHMI), where vaccinated volunteers are exposed to malaria-infected mosquito bites to evaluate protective immunity.

Other names

AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge-University of Oxford-malaria